4//SEC Filing
Silva Paul M 4
Accession 0001209191-21-014749
CIK 0000875320other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 4:23 PM ET
Size
12.8 KB
Accession
0001209191-21-014749
Insider Transaction Report
Form 4
Silva Paul M
V.P. and Corporate Controller
Transactions
- Sale
Common Stock
2021-02-25$213.12/sh−452$96,330→ 15,268 total - Tax Payment
Common Stock
2021-02-24$217.57/sh−864$187,980→ 15,964 total - Sale
Common Stock
2021-02-25$211.80/sh−244$51,679→ 15,720 total - Sale
Common Stock
2021-02-25$214.32/sh−258$55,295→ 15,010 total - Sale
Common Stock
2021-02-25$216.25/sh−126$27,248→ 14,884 total
Holdings
- 169(indirect: By 401(k))
Common Stock
Footnotes (6)
- [F1]Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $211.80 (range $211.57 to $212.07).
- [F3]Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.82 to $213.79).
- [F5]Open market sales reported on this line occurred at a weighted average price of $214.32 (range $213.90 to $214.69).
- [F6]Open market sales reported on this line occurred at a weighted average price of $216.25 (range $215.79 to $216.76).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001446372
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 4:23 PM ET
- Size
- 12.8 KB